Alnylam Pharmaceuticals Inc at Piper Sandler Healthcare Conference (Virtual) Transcript
Good morning. My name is Ted Tenthoff, and I'm a senior biotechnology analyst at Piper Sandler. Thank you for joining us for this year's Virtual Healthcare Conference.
As you well know, Alnylam is the leading RNAi company, now with 3 wholly owned approved medicines and a partner product with Novartis approved in Europe, plus a really rich and exciting pipeline of future therapies.
Here with us today is CEO, John Maraganore, who recently announced his intention to retire from Alnylam. And before we begin, I just want to thank you, John, for everything you've done for patients, investors, biotech community, for me in teaching me this business over the last 18-plus years. I remember when we were taking Alnylam public in 2004, and you had a vision to create a novel therapeutic modality. Well, you've accomplish that ambitious goal and much, much more. Alnylam is now a $20-plus billion company with a clear path for future growth. And John, thank you for everything you've done sincerely.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
